A Phase 2 Study of BGB-11417 in People With Waldenström's Macroglobulinemia


Full Title

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia


In this study, researchers want to learn if BGB-11417 works well against Waldenström’s macroglobulinemia (WM). The people in this study have WM that keeps growing or came back after treatment.

BGB-11417 blocks a protein called Bcl-2, which helps blood cancer cells to live and grow. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have WM that keeps growing or came back even after treatment.
  • Have recovered from the serious side effects of prior cancer therapies before taking BGB-11417.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Lia Palomba’s office at 646-608-3711.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID